Evaluation of the treatment efficacy of immune plasma ın patients treated ın intensive care with the diagnosis of COVİD-19
Emel Yıldız, Murat Emre Tokur, Buğra Özel, Özlem Arık, Canan Balcı
Kütahya sağlık bilimleri üniversitesi
Giriş:
Treatment in COVID-19 infection consist of antiviral, immunomodulatory, and supportive treatments(1). Convalescent plasma or hyperimmune plasma refers to the plasma consisting of high titer polyclonal antibodies against the virus and are among the immunomodulatory treatments(2). Although it has been reported that immune plasma (IP) in the treatment of COVID-19 reduces hospital stay and mortality, the efficacy of immune plasma (IP) in COVID-19 infection is not clear yet. The present study aims to investigate the efficacy of immune plasma in patients who are followed up in the intensive care unit with the diagnosis of COVID-19.
Gereç ve Yöntem: Patients in the pandemic intensive care unit with COVID-19 infection were divided into two groups as those who received IP treatment (Group 1; n=28) and those who did not (Group 2; n=25), and retrospectively examined. Leukocyte, neutrophil, lymphocyte, platelet count, C -reactive protein (CRP), lactate-dehydrogenase (LDH), ferritin, D-dimer, total bilirubin, and creatine values of the patients were recorded
Bulgular: There was no statistically significant difference between Group 1 and Group 2 in terms of the presence of mechanical ventilation support and tracheostomy, comorbidities, laboratory values, CRP, SOFA, Apache scores. Mortality was 61% in Group 1 and 52% in Group 2.
Tartışma ve Sonuç: Our findings revealed that IP was not effective on recovery and mortality in treating ICU patients with COVID-19 infection. More studies are needed to investigate the efficacy of administering immunomodulatory therapies on the outcome before the hyperinflammatory process starts
|